Будь ласка, використовуйте цей ідентифікатор, щоб цитувати або посилатися на цей матеріал:
https://dspace.uzhnu.edu.ua/jspui/handle/lib/68807
Повний запис метаданих
Поле DC | Значення | Мова |
---|---|---|
dc.contributor.author | Дутко, Олександр Олександрович | - |
dc.contributor.author | Сірчак, Єлизавета Степанівна | - |
dc.contributor.author | Устич, Олена Василівна | - |
dc.contributor.author | Лопіт, Михайло Михайлович | - |
dc.contributor.author | Грига, Василь Іванович | - |
dc.contributor.author | Корнаш, Володимир В | - |
dc.date.accessioned | 2024-12-20T19:55:37Z | - |
dc.date.available | 2024-12-20T19:55:37Z | - |
dc.date.issued | 2024-10 | - |
dc.identifier.citation | Sirchak, Y.S., Kornash, V. V., Dutko, O. O., Lopit, M. M. Ustych, O. V., Griga, V. I. (2024). Differentiated approach to management of patients with irritable bowel syndrome and ulcerative colitis in non-alcoholic fatty liver disease. Wiadomosci lekarskie (Warsaw, Poland: 1960), 77(10), 2002-2007. | uk |
dc.identifier.issn | 0043-5147 | - |
dc.identifier.issn | 2719-342X | - |
dc.identifier.uri | https://dspace.uzhnu.edu.ua/jspui/handle/lib/68807 | - |
dc.description.abstract | Aim: To determine the main clinical and laboratory features and severity of colon dysbiosis in irritable bowel syndrome (IBS) and IBD in patients with NAFLD. Materials and Methods: 80 patients with NAFLD were examined. Patients were divided into two groups. Group 1 (n=40) included patients with NAFLD in combination with ulcerative colitis (UC), and group 2 (n=40) included patients with NAFLD and IBS (clinically manifested by diarrhoea). At patients diagnosed the level of faecal calprotectin (FC) and a1-antirpsin (a1-AT). Changes in the quantitative and qualitative composition of the colon microflora were assessed. Results: In both groups of examined patients, a decrease of Bifidobacteria and Lactobacilli, as well as Enterococcus and E. coli with normal enzymatic properties was found compared with the control group. In patients with NAFLD and IBD, an increase in the level of FC was found in 23.8 times compared with the control group. As expected, there was an increase in the level of a1-AT in the blood serum, faeces and its clearance in patients of group 1. Conclusions: In patients with NAFLD, both UC and ІBS have similar clinical symptoms. An effective biomarker for differentiating and choosing treatment tactics in patients with NAFLD and UC is the determination of the level of FC. | uk |
dc.language.iso | en | uk |
dc.publisher | Aluna Publishing | uk |
dc.relation.ispartofseries | 77;10 | - |
dc.subject | non-alcoholic fatty liver disease | uk |
dc.subject | inflammatory bowel disease | uk |
dc.subject | ulcerative colitis | uk |
dc.subject | irritable bowel syndrome | uk |
dc.subject | diagnostics | uk |
dc.subject | calprotectin | uk |
dc.subject | a1-antitrypsin | uk |
dc.subject | colon dysbiosis | uk |
dc.title | Differentiated approach to management of patients with irritable bowel syndrome and ulcerative colitis in non-alcoholic fatty liver disease | uk |
dc.type | Text | uk |
dc.pubType | Стаття | uk |
Розташовується у зібраннях: | Наукові публікації кафедри хірургічних хвороб |
Файли цього матеріалу:
Файл | Опис | Розмір | Формат | |
---|---|---|---|---|
Differentiated approach.pdf | 123.27 kB | Adobe PDF | Переглянути/Відкрити |
Усі матеріали в архіві електронних ресурсів захищені авторським правом, всі права збережені.